Mavacamten

Chemical formula: C₁₅H₁₉N₃O₂  Molecular mass: 273.331 g/mol  PubChem compound: 117761397

Therapeutic indications

Mavacamten is indicated for:

Obstructive hypertrophic cardiomyopathy

Population group: only adults (18 years old or older)

Mavacamten is indicated for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Mavacamten is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Strong CYP3A4 inhibitors in patients with CYP2C19 poor metaboliser phenotype

Strong CYP3A4 inhibitors and additionally CYP2C19 poor metabolizer

Strong CYP2C19 and CYP3A4 inhibitor

Strong CYP2C19 inhibitors and additionally Strong CYP3A4 inhibitors

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2023: CAMZYOS Hard capsule
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈